2025年商业健康保险对创新药械的总赔付金额约147亿元

Group 1 - The core viewpoint of the articles emphasizes the continuous expansion of commercial health insurance in China, enhancing health protection services and capabilities [1][2] - By 2025, the estimated total compensation amount for innovative drugs and medical devices from commercial health insurance is approximately 14.7 billion yuan, showing rapid growth for four consecutive years [1] - The insurance industry is experiencing growth driven by both policy support and market demand, leading to an increase in business scale, product variety, and service capabilities [1] Group 2 - As of the third quarter of 2025, insurance funds have directly invested nearly 30 billion yuan in the medical and elderly care sectors, covering various sub-sectors such as biotechnology, new drug technology, and medical devices [1] - Indirect investments in the healthcare sector have exceeded 250 billion yuan, focusing on core areas of health such as medical services, innovative drugs, and medical data [1] - The Actuarial Association is working on developing a comprehensive commercial medical insurance product system to improve the matching of insurance rates with underwriting risks [1]